Go Pro

Avantor (AVTR) Competitors

Avantor logo
$14.26 +0.30 (+2.15%)
Closing price 08/20/2026 03:58 PM Eastern
Extended Trading
$14.33 +0.07 (+0.48%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AVTR vs. RVTY, TMO, ILMN, MTD, and MEDP

Should you buy Avantor stock or one of its competitors? Avantor's main competitors and comparable companies include Revvity (RVTY), Thermo Fisher Scientific (TMO), Illumina (ILMN), Mettler-Toledo International (MTD), and Medpace (MEDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Avantor compare to Revvity?

Revvity (NYSE:RVTY) and Avantor (NYSE:AVTR) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Revvity has a net margin of 8.16% compared to Avantor's net margin of -8.81%. Avantor's return on equity of 9.92% beat Revvity's return on equity.

Company Net Margins Return on Equity Return on Assets
Revvity8.16% 8.34% 5.01%
Avantor -8.81%9.92%4.75%

Revvity has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Avantor has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

86.7% of Revvity shares are held by institutional investors. Comparatively, 95.1% of Avantor shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Comparatively, 0.3% of Avantor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revvity presently has a consensus target price of $108.36, indicating a potential downside of 12.62%. Avantor has a consensus target price of $12.00, indicating a potential downside of 15.85%. Given Revvity's stronger consensus rating and higher probable upside, equities analysts plainly believe Revvity is more favorable than Avantor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revvity
0 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Avantor
1 Sell rating(s)
15 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.06

Revvity has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revvity$2.86B4.85$241.20M$2.1059.06
Avantor$6.56B1.47-$530.20M-$0.84N/A

In the previous week, Avantor had 9 more articles in the media than Revvity. MarketBeat recorded 16 mentions for Avantor and 7 mentions for Revvity. Avantor's average media sentiment score of 1.00 beat Revvity's score of 0.81 indicating that Avantor is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revvity
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Avantor
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Revvity beats Avantor on 11 of the 16 factors compared between the two stocks.

How does Avantor compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Avantor (NYSE:AVTR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Thermo Fisher Scientific had 94 more articles in the media than Avantor. MarketBeat recorded 110 mentions for Thermo Fisher Scientific and 16 mentions for Avantor. Thermo Fisher Scientific's average media sentiment score of 1.60 beat Avantor's score of 1.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Thermo Fisher Scientific
105 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Avantor
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Thermo Fisher Scientific has a net margin of 15.04% compared to Avantor's net margin of -8.81%. Thermo Fisher Scientific's return on equity of 17.09% beat Avantor's return on equity.

Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific15.04% 17.09% 8.12%
Avantor -8.81%9.92%4.75%

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 95.1% of Avantor shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 0.3% of Avantor shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Thermo Fisher Scientific has higher revenue and earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$44.56B5.21$6.70B$18.5933.79
Avantor$6.56B1.47-$530.20M-$0.84N/A

Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Avantor has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Thermo Fisher Scientific presently has a consensus price target of $619.41, suggesting a potential downside of 1.41%. Avantor has a consensus price target of $12.00, suggesting a potential downside of 15.85%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, equities research analysts clearly believe Thermo Fisher Scientific is more favorable than Avantor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
0 Sell rating(s)
6 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.78
Avantor
1 Sell rating(s)
15 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.06

Summary

Thermo Fisher Scientific beats Avantor on 15 of the 17 factors compared between the two stocks.

How does Avantor compare to Illumina?

Avantor (NYSE:AVTR) and Illumina (NASDAQ:ILMN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Illumina has a net margin of 18.36% compared to Avantor's net margin of -8.81%. Illumina's return on equity of 29.84% beat Avantor's return on equity.

Company Net Margins Return on Equity Return on Assets
Avantor-8.81% 9.92% 4.75%
Illumina 18.36%29.84%12.17%

Avantor presently has a consensus price target of $12.00, indicating a potential downside of 15.85%. Illumina has a consensus price target of $188.40, indicating a potential downside of 11.65%. Given Illumina's stronger consensus rating and higher probable upside, analysts clearly believe Illumina is more favorable than Avantor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avantor
1 Sell rating(s)
15 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.06
Illumina
2 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.47

Illumina has lower revenue, but higher earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avantor$6.56B1.47-$530.20M-$0.84N/A
Illumina$4.49B7.16$850M$5.3639.78

95.1% of Avantor shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 0.3% of Avantor shares are owned by company insiders. Comparatively, 2.9% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Avantor has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Illumina has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

In the previous week, Illumina had 11 more articles in the media than Avantor. MarketBeat recorded 27 mentions for Illumina and 16 mentions for Avantor. Illumina's average media sentiment score of 1.52 beat Avantor's score of 1.00 indicating that Illumina is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avantor
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Illumina
21 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Illumina beats Avantor on 15 of the 17 factors compared between the two stocks.

How does Avantor compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Avantor (NYSE:AVTR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Mettler-Toledo International currently has a consensus target price of $1,461.27, suggesting a potential upside of 4.91%. Avantor has a consensus target price of $12.00, suggesting a potential downside of 15.85%. Given Mettler-Toledo International's stronger consensus rating and higher possible upside, equities research analysts plainly believe Mettler-Toledo International is more favorable than Avantor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mettler-Toledo International
0 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.46
Avantor
1 Sell rating(s)
15 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.06

In the previous week, Avantor had 7 more articles in the media than Mettler-Toledo International. MarketBeat recorded 16 mentions for Avantor and 9 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 1.37 beat Avantor's score of 1.00 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mettler-Toledo International
8 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avantor
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mettler-Toledo International has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, Avantor has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Mettler-Toledo International has a net margin of 21.91% compared to Avantor's net margin of -8.81%. Avantor's return on equity of 9.92% beat Mettler-Toledo International's return on equity.

Company Net Margins Return on Equity Return on Assets
Mettler-Toledo International21.91% -1,212.14% 25.11%
Avantor -8.81%9.92%4.75%

Mettler-Toledo International has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$4.03B6.93$869.19M$44.4331.35
Avantor$6.56B1.47-$530.20M-$0.84N/A

95.1% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 95.1% of Avantor shares are held by institutional investors. 0.7% of Mettler-Toledo International shares are held by insiders. Comparatively, 0.3% of Avantor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Mettler-Toledo International beats Avantor on 12 of the 16 factors compared between the two stocks.

How does Avantor compare to Medpace?

Medpace (NASDAQ:MEDP) and Avantor (NYSE:AVTR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

78.0% of Medpace shares are held by institutional investors. Comparatively, 95.1% of Avantor shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 0.3% of Avantor shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Medpace has a net margin of 17.67% compared to Avantor's net margin of -8.81%. Medpace's return on equity of 110.15% beat Avantor's return on equity.

Company Net Margins Return on Equity Return on Assets
Medpace17.67% 110.15% 24.84%
Avantor -8.81%9.92%4.75%

Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Avantor has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Medpace currently has a consensus price target of $584.18, suggesting a potential downside of 4.65%. Avantor has a consensus price target of $12.00, suggesting a potential downside of 15.85%. Given Medpace's stronger consensus rating and higher possible upside, research analysts clearly believe Medpace is more favorable than Avantor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace
0 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.23
Avantor
1 Sell rating(s)
15 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.06

Medpace has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medpace$2.53B6.76$451.12M$17.0635.91
Avantor$6.56B1.47-$530.20M-$0.84N/A

In the previous week, Medpace had 7 more articles in the media than Avantor. MarketBeat recorded 23 mentions for Medpace and 16 mentions for Avantor. Medpace's average media sentiment score of 1.13 beat Avantor's score of 1.00 indicating that Medpace is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medpace
18 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avantor
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Medpace beats Avantor on 14 of the 16 factors compared between the two stocks.

Get Avantor News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTR vs. The Competition

MetricAvantorLife Sciences Tools & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$9.44B$9.97B$7.36B$24.27B
Dividend YieldN/A1.46%2.54%3.70%
P/E Ratio-16.9859.65268.9529.98
Price / Sales1.47110.36625.6520.03
Price / Cash9.2226.5278.1332.31
Price / Book1.7137.2313.026.75
Net Income-$530.20M$56.67B$3.46B$1.07B
7 Day Performance4.43%3.91%1.10%-1.33%
1 Month Performance29.93%8.00%3.99%1.60%
1 Year Performance13.67%26.67%26.51%17.24%

Avantor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTR
Avantor
2.2905 of 5 stars
$14.26
+2.1%
$12.00
-15.8%
+10.7%$9.44B$6.56BN/A13,500
RVTY
Revvity
3.2912 of 5 stars
$116.36
-0.4%
$108.36
-6.9%
+35.2%$13.04B$2.86B55.4111,000
TMO
Thermo Fisher Scientific
4.4991 of 5 stars
$586.62
-0.3%
$619.41
+5.6%
+27.0%$217.52B$44.56B31.56125,000
ILMN
Illumina
2.881 of 5 stars
$193.13
+1.2%
$188.40
-2.4%
+111.5%$28.82B$4.34B36.038,650
MTD
Mettler-Toledo International
3.4294 of 5 stars
$1,417.73
-0.1%
$1,461.27
+3.1%
+6.1%$28.43B$4.03B31.9118,100

Related Companies and Tools


This page (NYSE:AVTR) was last updated on 8/21/2026 by MarketBeat.com Staff.
From Our Partners